PART I . Overview We are a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. We are focused on expanding patient access, progressing our pipeline toward key milestones, and delivering meaningful therapeutics. Our vision is realized through disciplined execution of our strategic plan and our core values patient centricity, integrity, accountability, innovation, and courage which gui...
Q2 FY2026 — expected 2026-08-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2025-12-31 | 0001434647-26-000011 | EDGAR | 71K words |
| 2025-03-12 | 2024-12-31 | 0001437749-25-007320 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0001437749-24-010430 | EDGAR | — |
| 2023-03-07 | 2022-12-31 | 0001437749-23-005703 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001437749-22-007725 | EDGAR | — |
| 2021-03-12 | 2020-12-31 | 0001437749-21-005785 | EDGAR | — |
| 2020-02-28 | 2019-12-31 | 0001437749-20-003965 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001437749-19-003789 | EDGAR | — |
| 2018-03-30 | 2017-12-31 | 0001437749-18-005932 | EDGAR | — |
| 2017-03-10 | 2016-12-31 | 0001437749-17-004317 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001434647-25-000011 | EDGAR | 32K words |
| 2025-08-12 | 2025-06-30 | 0001628280-25-039967 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001437749-25-016523 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001437749-24-034916 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001437749-24-026474 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001437749-24-015705 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001437749-23-030690 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001437749-23-023716 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001437749-23-014683 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001437749-22-026683 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001437749-22-020394 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001437749-22-012182 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-16 | 0001434647-26-000015 | EDGAR | 1K words |
| 2026-03-09 | 0001434647-26-000009 | EDGAR | — |
| 2025-12-17 | 0001434647-25-000018 | EDGAR | — |
| 2025-12-02 | 0001434647-25-000015 | EDGAR | — |
| 2025-11-20 | 0001193125-25-289865 | EDGAR | — |
| 2025-11-05 | 0001434647-25-000009 | EDGAR | — |
| 2025-08-12 | 0001628280-25-039883 | EDGAR | — |
| 2025-05-29 | 0001193125-25-130714 | EDGAR | — |
| 2025-05-13 | 0001437749-25-016452 | EDGAR | — |
| 2025-04-07 | 0001193125-25-073991 | EDGAR | — |
295 total filings indexed. 263 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001434647 |
| Ticker | ZVRA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.zevra.com |
| Listed | 2015-04-16 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report